"Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the independent Data and Safety Monitoring Board ("DSMB") for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015."
However, Phase III "NEWS" probably will have little influence on pps. It will be merely stop or continue -- nothing more -- no data. This is true for interim analyses. This was reaffirmed by purported email from IR -- there will merely be a continue/stop announcement.
The first go-ahead on 4-27-15 resulted in a 10% pop from .60 to .66 after hours and then the next day it was back to .60.
Dan Ward and $heff have stated that the interim analysis will not benefit shareholders
Even with a go-ahead the top line results are not until late 2016 at the earliest. Prior to that AEZS must find a way to stay Nasdaq listed, a prospect which is dwindling as the market cap dives down.
News 
Market Data 
Discover 
AI
